Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction

Molecular Imaging and Biology

Volumn 13, Issue 1, 2011, Pages 178-186

  Lorenzen, Sylvie ^a   Panzram, Ben ^b   Keller, Gisela ^c   Lordick, Florian ^d   Herrmann, Ken ^c   Becker, Karin ^c   Langer, Ruppert ^c   Schwaiger, Markus ^c   Siewert, Jorg Rudiger ^a   Ott, Katja ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

AEG I II; FDG PET; MUNICON trial; Polymorphism; VEGF

Indexed keywords

FLUORODEOXYGLUCOSE F 18; VASCULOTROPIN;

ADENOCARCINOMA; ADULT; ALOPECIA; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG UPTAKE; EVENT FREE SURVIVAL; FATIGUE; FEMALE; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAND FOOT SYNDROME; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; POLYMORPHISM, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79551579334     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0330-0     Document Type: Article

References (43)

1. K Ott WA Weber F Lordick, et al. 2006 Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction J. Clin. Oncol. 24 4692 4698 10.1200/JCO.2006.06.7801 16966684
2. WA Weber K Ott K Becker, et al. 2001 Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J. Clin. Oncol. 19 3058 3065 1:STN:280:DC%2BD3MzksFGhsQ%3D%3D 11408502
3. F Lordick K Ott BJ Krause, et al. 2007 PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol. 8 797 805 10.1016/S1470-2045(07)70244-9 17693134
4. Siewert J.R.; Lordick F.; Ott K., et al. (2007) Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg 246:624-628; discussion 628-631
5. M Westerterp HL van Westreenen JB Reitsma, et al. 2005 Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review Radiology. 236 841 851 10.1148/radiol.2363041042 16118165
6. HA Wieder AJ Beer F Lordick, et al. 2005 Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction J. Nucl. Med. 46 2029 2034 1:CAS:528: DC%2BD28XivVSrsQ%3D%3D 16330567
7. Q Jin K Hemminki K Enquist, et al. 2005 Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis Clin. Cancer. Res. 11 3647 3653 1:CAS:528:DC%2BD2MXktFyrsbs%3D 10.1158/1078-0432.CCR-04-1803 15897560
8. YS Chung K Maeda M Sowa 1996 Prognostic value of angiogenesis in gastro-intestinal tumours Eur J Cancer 32A 2501 2505 1:STN:280: DyaK2s3ht1CrsQ%3D%3D 10.1016/S0959-8049(96)00382-6 9059339
9. K Maeda YS Chung Y Ogawa, et al. 1996 Prognostic value of vascular endothelial growth factor expression in gastric carcinoma Cancer 77 858 863 1:STN:280:DyaK287osFelsA%3D%3D 10.1002/(SICI)1097-0142(19960301)77:5<858:: AID-CNCR8>3.0.CO;2-A 8608475
10. M Yamamori T Sakaeda T Nakamura, et al. 2004 Association of VEGF genotype with mRNA level in colorectal adenocarcinomas Biochem Biophys Res Commun 325 144 150 1:CAS:528:DC%2BD2cXpt1artLk%3D 10.1016/j.bbrc.2004.10.005 15522212
11. G Mor I Visintin Y Lai, et al. 2005 Serum protein markers for early detection of ovarian cancer Proc Natl Acad Sci USA 102 7677 7682 1:CAS:528:DC%2BD2MXkslOmsrk%3D 10.1073/pnas.0502178102 15890779
12. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J. Clin. Oncol. 23 1011 1027 1:CAS:528:DC%2BD2MXit1Gnsro%3D 10.1200/JCO.2005.06.081 15585754
13. C Wong TL Wellman KM Lounsbury 2003 VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer Gynecol. Oncol. 91 513 517 1:CAS:528:DC%2BD3sXpvVWlsb4%3D 10.1016/j.ygyno.2003.08.022 14675669
14. RT Poon ST Fan J Wong 2001 Clinical implications of circulating angiogenic factors in cancer patients J. Clin. Oncol. 19 1207 1225 1:CAS:528:DC%2BD3MXhvFertrc%3D 11181687
15. AJ Karayiannakis KN Syrigos A Polychronidis, et al. 2002 Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery Ann. Surg. 236 37 42 10.1097/00000658-200207000-00007 12131083
16. MA Shah RK Ramanathan DH Ilson, et al. 2006 Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J. Clin. Oncol. 24 5201 5206 1:CAS:528:DC%2BD28XhtlemurbM 10.1200/JCO.2006.08.0887 17114652
17. SP Balasubramanian NJ Brown MW Reed 2002 Role of genetic polymorphisms in tumour angiogenesis Br. J. Cancer. 87 1057 1065 1:CAS:528:DC%2BD38XotFWru7s%3D 10.1038/sj.bjc.6600625 12402142
18. SJ Bae JW Kim H Kang, et al. 2008 Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea Anticancer. Res. 28 1271 1276 1:CAS:528: DC%2BD1cXmt1ehurs%3D 18505065
19. C Yapijakis E Vairaktaris S Vassiliou, et al. 2007 The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer J. Cancer. Res. Clin. Oncol. 133 787 791 1:CAS:528:DC%2BD2sXpsFehurs%3D 10.1007/s00432-007-0240-y 17564725
20. A Ruzzo F Graziano K Kawakami, et al. 2006 Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy J. Clin. Oncol. 24 1883 1891 1:CAS:528: DC%2BD28XkvVajtLk%3D 10.1200/JCO.2005.04.8322 16622263
21. JG Kim SK Sohn YS Chae, et al. 2007 Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer Ann. Oncol. 18 1030 1036 1:STN:280:DC%2BD2szntVamtw%3D%3D 10.1093/annonc/mdm085 17426061
22. N Tzanakis M Gazouli G Rallis, et al. 2006 Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival J. Surg. Oncol. 94 624 630 1:CAS:528:DC%2BD28XhtlCisb3K 10.1002/jso.20619 17111394
23. H Lu XO Shu Y Cui, et al. 2005 Association of genetic polymorphisms in the VEGF gene with breast cancer survival Cancer. Res. 65 5015 5019 1:CAS:528:DC%2BD2MXltFemtLs%3D 10.1158/0008-5472.CAN-04-2786 15958542
24. LA Hefler A Mustea D Konsgen, et al. 2007 Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer Clin. Cancer. Res. 13 898 901 1:CAS:528:DC%2BD2sXhsVyrsL4%3D 10.1158/1078-0432.CCR-06- 1008 17289883
25. D Li M Frazier DB Evans, et al. 2006 Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer J. Clin. Oncol. 24 1720 1728 1:CAS:528:DC%2BD28XksVKgtb8%3D 10.1200/JCO.2005.04.4206 16520463
26. AM Schultheis G Lurje KE Rhodes, et al. 2008 Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab Clin. Cancer. Res. 14 7554 7563 1:CAS:528:DC%2BD1cXhtlylur3K 10.1158/1078-0432.CCR-08-0351 19010874
27. P Krippl U Langsenlehner W Renner, et al. 2003 A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk Int. J. Cancer. 106 468 471 1:CAS:528:DC%2BD3sXmtlyqu7Y%3D 10.1002/ijc.11238 12845639
28. W Renner S Kotschan C Hoffmann, et al. 2000 A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels J. Vasc. Res. 37 443 448 1:CAS:528:DC%2BD3MXoslGmsQ%3D%3D 10.1159/000054076 11146397
29. PA Bradbury R Zhai C Ma, et al. 2009 Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis Clin. Cancer. Res. 15 4680 4685 1:CAS:528:DC%2BD1MXosV2ltLk%3D 10.1158/1078-0432.CCR-09-0192 19584152
30. G Wolf RM Aigner G Schaffler, et al. 2004 The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake Breast. Cancer. Res. Treat. 88 205 208 1:CAS:528:DC%2BD2MXht1Kjt7o%3D 10.1007/s10549-004-0724-2 15609122
31. FG Bader F Lordick U Fink, et al. 2008 Paclitaxel in the neoadjuvant treatment for adenocarcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up Onkologie 31 366 372 1:CAS:528:DC%2BD1cXotFCisL4%3D 10.1159/000135515 18596383
32. K Ott FG Bader F Lordick, et al. 2009 Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center Ann. Surg. Oncol. 16 1017 1025 10.1245/s10434-009-0336-5 19189186
33. K Ott A Sendler K Becker, et al. 2003 Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study Gastric. Cancer. 6 159 167 1:CAS:528: DC%2BD3sXns1Gqu74%3D 10.1007/s10120-003-0245-4 14520529
34. A Chak MI Canto GS Cooper, et al. 2000 Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients Cancer. 88 1788 1795 1:STN:280:DC%2BD3c3isFGruw%3D%3D 10.1002/(SICI)1097-0142(20000415) 88:8<1788::AID-CNCR5>3.0.CO;2-6 10760753
35. AM Lowy PF Mansfield SD Leach, et al. 1999 Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer Ann. Surg. 229 303 308 1:STN:280:DyaK1M7nsVKmug%3D%3D 10.1097/00000658- 199903000-00001 10077040
36. K Becker JD Mueller C Schulmacher, et al. 2003 Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy Cancer. 98 1521 1530 10.1002/cncr.11660 14508841
37. R Bos JJ van Der Hoeven E van Der Wall, et al. 2002 Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J. Clin. Oncol. 20 379 387 1:CAS:528:DC%2BD38XovVKisQ%3D%3D 10.1200/JCO.20.2.379 11786564
38. N Avril CA Rose M Schelling, et al. 2000 Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J. Clin. Oncol. 18 3495 3502 1:STN:280:DC%2BD3M%2Fhsl2hsA%3D%3D 11032590
39. G Lurje W Zhang AM Schultheis, et al. 2008 Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer Ann. Oncol. 19 1734 1741 1:STN:280:DC%2BD1cnhslOnsg%3D%3D 10.1093/annonc/mdn368 18550579
40. RS Heist R Zhai G Liu, et al. 2008 VEGF polymorphisms and survival in early-stage non-small-cell lung cancer J. Clin. Oncol. 26 856 862 1:CAS:528:DC%2BD1cXjtFelsb8%3D 10.1200/JCO.2007.13.5947 18281657
41. JG Kim YS Chae SK Sohn, et al. 2008 Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer Clin. Cancer. Res. 14 62 66 1:CAS:528:DC%2BD1cXoslOn 10.1158/1078-0432.CCR-07- 1537 18172253
42. HA Wieder H Geinitz R Rosenberg, et al. 2007 PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer Eur. J. Nucl. Med. Mol. Imaging. 34 878 883 1:CAS:528:DC%2BD2sXltl2htL4%3D 10.1007/s00259-006-0292-2 17195074
43. K Ott H Vogelsang N Marton, et al. 2006 The thymidylate synthase tandem repeat promoter polymorphism: a predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer Int. J. Cancer. 119 2885 2894 1:CAS:528:DC%2BD28Xht1yqt7jE 10.1002/ijc.22235 16929515